Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
300%(3 trials)
Terminated
4(67%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

16.7%

1 of 6 finished

Non-Completion Rate

83.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(1)
Terminated(5)

Detailed Status

Terminated4
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
20.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

withdrawn117%
completed117%
terminated467%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_2

Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

NCT06682234
terminatedphase_2

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

NCT06585150
terminatedphase_2

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
terminatedphase_2

Study of Obeldesivir in Children and Adolescents With COVID-19

NCT05996744
completedphase_3

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

NCT05715528
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06682234Phase 2

Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

Withdrawn
NCT06585150Phase 2

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Terminated
NCT06784973Phase 2

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Terminated
NCT05996744Phase 2

Study of Obeldesivir in Children and Adolescents With COVID-19

Terminated
NCT05715528Phase 3

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

Completed
NCT05603143Phase 3

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6